CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen-Reference-Cited by-同舟云学术

CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen

Published:2015-10-08 Issue:2 Volume:29 Page:184-195
ISSN:0934-0874
Container-title:Transplant International
language:en
Short-container-title:Transpl Int

Author:

Thibault Gilles¹,Paintaud Gilles²,Legendre Christophe³,Merville Pierre⁴,Coulon Maxime¹,Chasseuil Elodie²,Ternant David²,Rostaing Lionel⁵,Durrbach Antoine⁶,Di Giambattista Fabienne⁷,Büchler Matthias⁸,Lebranchu Yvon⁸

Affiliation:

1. Laboratoire d'Immunologie; Bretonneau Hospital; CHRU de Tours; CNRS; GICC UMR 7292; Université François-Rabelais de Tours; Tours France

2. Laboratoire de Pharmacologie-Toxicologie; Bretonneau Hospital; CHRU de Tours; CNRS; GICC UMR 7292; Université François-Rabelais de Tours; Tours France

3. Service de Nephrologie-Transplantation; Hôpital Necker; Assistance Publique-Hôpitaux de Paris; Université Paris Descartes; INSERM U 845; Paris France

4. Department of Nephrology, Transplantation and Dialysis; CHU Bordeaux; Pellegrin Hospital; UMR-CNRS 5164; Bordeaux University; Bordeaux France

5. Department of Nephrology, Dialysis and Organ Transplantation; Rangueil Hospital; Toulouse France

6. Department of Nephrology; INSERM UMR 1197; Kremlin Bicetre Hospital; Le Kremlin-Bicêtre France

7. Novartis Pharma SAS; Rueil-Malmaison France

8. Department of Nephrology and Clinical Immunology; Bretonneau Hospital; CHRU de Tours; EA4245, Université François-Rabelais de Tours; Tours France

Funder

Novartis Pharma SAS, France

Publisher

Frontiers Media SA

Subject

Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tri.12688/fullpdf

Reference29 articles.

1. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials;Adu;Br Med J,2003

2. Interleukin 2 receptor antagonists for kidney transplant recipients;Webster;Cochrane Database Syst Rev,2010

3. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group;Nashan;Lancet,1997

4. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy;Lebranchu;Am J Transplant,2002

5. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation;Amlot;Transplantation,1995

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition model;British Journal of Clinical Pharmacology;2022-02

2. An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients;Brazilian Journal of Medical and Biological Research;2021

3. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis;Transplantation;2019-10

4. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans;Clinical Pharmacokinetics;2018-05-26

5. Overview of Immunosuppressive Therapy in Solid Organ Transplantation;Anesthesiology Clinics;2017-09